Navigation Links
Blocking molecular pathway with whimsical name possible therapeutic target for pancreatic cancer
Date:12/14/2008

A possible new therapeutic target for pancreatic cancer, the most lethal form of human cancer, has been identified in the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," according to researchers at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

In their studies with the fruit fly, Drosophila melanogaster, at the Mayo Clinic College of Medicine in Minnesota, scientists found a link between the "Seven-In-Absentia" or SINA gene and the aggressive cellular transformation, oncogenesis and metastasis that characterize pancreatic cancer.

Scientists already knew that a mutation in the K-RAS gene underlies the abnormal, excessive cell growth of pancreatic cancer.

Because the mutated form of this growth-promoting gene is hyperactivated, a major signaling pathway that drives cell growth is in over-drive in most patients with this cancer.

The "Seven-In-Absentia-Homolog" (SIAH) protein seems to work as a check and balance mechanism in the K-RAS pathway by chewing up and turning off the excessive growth-promoting proteins produced by the hyperactive, mutated form of the gene, says Amy Tang whose Mayo lab conducted the research.

"By attacking the SIAH-based protein degrading machinery, we block tumor formation in one of the most aggressive human cancers cells known," she reports.

Because of these results, SIAH may be an attractive new target for novel anti-RAS and anti-cancer therapy in pancreatic cancer, the median survival of which is only six months, and the mortality rate is 95 percent.

By inhibiting SIAH function, Tang and her colleagues were able to completely abolish both tumorigenesis and metastasis of human pancreatic cancer cells that were growing in "nude" mice that have immune system deficits that prevent them from rejecting foreign tissue.

"It is likely to move into the clinical setting for study as an interventional treatment in pancreatic cancer in human patients," Tang says, referring to the SIAH inhibition.

SINA produces a family of RING domain E3 ubiquitin ligases. In all creatures, ubiquitin ligases turn cell pathways on or off by degrading proteins.

In humans, the SIAH ubiquitin ligases sit smack in the middle of the molecular pathway that leads to pancreatic cancer, Tang explains.

The Tang lab found that SIAH ubiquitin ligases were specifically and markedly "upregulated" in pancreatic cancers.

The increased SIAH expression seemed to correlate with increased grades and aggressiveness of pancreatic cancer. Moreover, SIAH is normally required for mammalian K-RAS signal transduction.


'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
American Society for Cell Biology
Source:Eurekalert

Related medicine news :

1. Blocking Potent Oxidant Could Prevent Morphine Tolerance
2. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
3. Blocking the effect of inflammation-causing cells lowered prostate cancer cells invasion
4. Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
5. Pennsylvania Medical Society and AARP Criticize Senator Specter for Blocking Bill to Protect Access to Doctors and Improve Medicare
6. A new molecular zip code, and a new drug target for Huntingtons disease
7. New knock-out gene model provides molecular clues to breast cancer
8. Molecular probe paints cancer cells in living animals, Stanford researchers find
9. Story ideas from molecular & cellular proteomics
10. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
11. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
Breaking Medicine Technology: